289 related articles for article (PubMed ID: 6597563)
21. The current state of multidrug-resistant gram-negative bacilli in North America.
Nicasio AM; Kuti JL; Nicolau DP
Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969
[TBL] [Abstract][Full Text] [Related]
22. Tigecycline: in-vitro performance as a predictor of clinical efficacy.
Hawkey P; Finch R
Clin Microbiol Infect; 2007 Apr; 13(4):354-62. PubMed ID: 17359318
[TBL] [Abstract][Full Text] [Related]
23. Basic design of beta-lactam antibiotics--cephalosporins.
Price KE; McGregor DN
Scand J Infect Dis Suppl; 1984; 42():50-63. PubMed ID: 6597562
[TBL] [Abstract][Full Text] [Related]
24. Evolution of beta-lactamase inhibitors.
Rolinson GN
J Reprod Med; 1988 Jun; 33(6 Suppl):571-3. PubMed ID: 3294401
[TBL] [Abstract][Full Text] [Related]
25. [Nontraditional beta-lactam antibiotics].
Vanderhaeghe H
Verh K Acad Geneeskd Belg; 1991; 53(1):39-58; discussion 58-9. PubMed ID: 2053420
[TBL] [Abstract][Full Text] [Related]
26. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
Sader HS; Tosin I; Sejas L; Miranda E
Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
[TBL] [Abstract][Full Text] [Related]
27. [Selection of resistant variants by broad spectrum beta-lactam antibiotics: to what extent is there cross resistance between imipenem and other beta-lactam antibiotics?].
Kahan F; Kropp H
Immun Infekt; 1986 Nov; 14(6):232-5. PubMed ID: 3100429
[TBL] [Abstract][Full Text] [Related]
28. The beta-lactamase problem: new therapeutic options.
Schito GC; Pesce A; Debbia EA; Marchese A
J Chemother; 1995 May; 7 Suppl 1():5-8. PubMed ID: 8618111
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of bacterial resistance to antibiotics.
Dever LA; Dermody TS
Arch Intern Med; 1991 May; 151(5):886-95. PubMed ID: 2025137
[TBL] [Abstract][Full Text] [Related]
30. In vitro activity of ertapenem: review of recent studies.
Wexler HM
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
[TBL] [Abstract][Full Text] [Related]
31. New molecules from old classes: revisiting the development of beta-lactams.
Page MG; Heim J
IDrugs; 2009 Sep; 12(9):561-5. PubMed ID: 19697275
[TBL] [Abstract][Full Text] [Related]
32. The evolution of antibiotic production and public health problems.
Mansford KR; Slocombe B
Chemioterapia; 1987 Jun; 6(3):234-40. PubMed ID: 3496977
[TBL] [Abstract][Full Text] [Related]
33. Mechanistic and clinical aspects of beta-lactam antibiotics and beta-lactamases.
Kotra LP; Mobashery S
Arch Immunol Ther Exp (Warsz); 1999; 47(4):211-6. PubMed ID: 10483868
[TBL] [Abstract][Full Text] [Related]
34. Phenotypic confirmation of extended-spectrum B-lactamases (ESBL) in clinical isolates of Escherichia coli and Klebsiella pneumoniae at the San Juan Veterans Affairs Medical Center.
Del Carmen Rodríguez M; Vera DE; Ramírez-Ronda CH; Saavedra S
P R Health Sci J; 2004 Sep; 23(3):207-15. PubMed ID: 15631176
[TBL] [Abstract][Full Text] [Related]
35. The impact of beta-lactamases on the development of novel antimicrobial agents.
Bush K
Curr Opin Investig Drugs; 2002 Sep; 3(9):1284-90. PubMed ID: 12498001
[TBL] [Abstract][Full Text] [Related]
36. In vitro activity of imipenem and six other beta-lactam antibiotics against aminoglycoside resistant gram-negative bacilli.
Bujdáková H; Kallová J; Lausová A; Kettner M
Microbios; 1995; 84(339):87-90. PubMed ID: 8628124
[TBL] [Abstract][Full Text] [Related]
37. Recent developments in antimicrobial therapy with beta-lactam antibiotics.
Beam TR
J Med; 1983; 14(4):307-36. PubMed ID: 6368719
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic considerations in using combinations of newer beta-lactam antibiotics.
Barriere SL
Clin Pharm; 1986 Jan; 5(1):24-33. PubMed ID: 3512153
[TBL] [Abstract][Full Text] [Related]
39. Aminoglycosides, imipenem, and aztreonam.
Johnson JG; Hardin TC
Clin Podiatr Med Surg; 1992 Apr; 9(2):443-64. PubMed ID: 1586911
[TBL] [Abstract][Full Text] [Related]
40. Toxicologic and pharmacologic considerations in the choice of empiric parenteral antibiotics.
Glauser MP; Neftel KA
Am J Med; 1986 May; 80(5C):64-9. PubMed ID: 3717190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
